医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Recognized as One of the Global 100 Most Sustainable Corporations for Second Consecutive Year

2017年01月20日 AM10:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights to the 2017 Global 100 Most Sustainable Corporations in the World Index. Takeda achieved this distinction for the second consecutive year and it is based on 14 key performance indicators, including energy productivity, innovation capacity, safety performance and leadership diversity.

Since 1781, Takeda has been committed to improving the future of healthcare. Inclusion in the Global 100 Index highlights the progress Takeda has made in its corporate responsibility efforts and sustainability planning.

“Takeda is honored to be included among such distinguished global corporations again,” said Haruhiko Hirate, Corporate Communications & Public Affairs Officer. “For Takeda, corporate social responsibility (CSR) is rooted in putting the patient at the center of everything we do. While we continuously strive to improve our business processes, we are also proud to engage in activities that promote a sustainable society and reflect our commitment to being a good corporate citizen.”

In conducting its activities, Takeda adheres to internationally recognized guidelines, such as the United Nations Global Compact’s 10 principles, and long-term international targets, such as the Sustainable Development Goals (SDGs).

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

Additional information about Takeda is available through its CSR Data Book 2016, http://www.takeda.com/csr/reports/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170119005533/en/

CONTACT

Media Contacts:
Japanese Media
Takeda
Pharmaceutical Company Limited
Tsuyoshi Tada, +81-3-3278-2417
tsuyoshi.tada@takeda.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
  • Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″